Specific immunosuppressive therapy by monoclonal anti-IL 2 receptor antibody and its synergistic action with cyclosporin.
The effects of anti-IL 2R mab treatment on local GVHR and on heterotopic cardiac allograft survival in rats were investigated. Anti IL 2 mab inhibited specifically both GVHR as well as allograft rejection. IL 2R-targeted therapy was superior to that of anti-T helper/inducer cell treatment, as it did not affect T subset distribution and did not reduce the number of circulating T lymphocytes. This therapy when combined with a low subtherapeutic dose of CsA exerted a strongly synergistic effect. The results support the concept of IL 2R-targeted therapy in suppressing undesired immune reactions with limited side effects.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface / Q000032:analysis; D003524:Cyclosporins / Q000008:administration & dosage*; D004357:Drug Synergism; D006084:Graft Rejection / Q000187:drug effects; D006087:Graft vs Host Reaction / Q000187:drug effects; D016027:Heart Transplantation; D007165:Immunosuppression Therapy; D008198:Lymph Nodes / Q000637:transplantation; D051381:Rats; D011919:Rats, Inbred Strains; D011971:Receptors, Immunologic / Q000276:immunology*; D015375:Receptors, Interleukin-2; D013154:Spleen / Q000637:transplantation; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface; D003524:Cyclosporins; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2